QLF31907

QLF31907 is a bispecific antibody developed by Qilu Pharmaceutical that targets both PD-L1 and 4-1BB. It acts as a conditional 4-1BB agonist in the tumor microenvironment, providing T-cell co-stimulation and enhancing T-cell proliferation and activation. The drug blocks PD-L1 to restore T-cell receptor (TCR) signaling while simultaneously binding to 4-1BB to deliver costimulatory signals essential for robust anti-tumor immune responses. This dual mechanism is designed to restrict 4-1BB activation primarily within the tumor microenvironment, potentially improving efficacy while minimizing systemic toxicity. QLF31907 is being investigated in clinical trials for advanced solid tumors and relapsed/refractory lymphoma, with ongoing studies also including melanoma and urothelial carcinoma[2][3][6][7][8].

Other names

anti-PD-L1/4-1BB bispecific antibody